Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP)
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse Large B Cell Lymphoma (DLBCL): The AvR-CHOP Study|
- Immune-related toxicity [ Time Frame: 12 months ]Immune-related toxicity which requires discontinuation of Avelumab
- Response Rate [ Time Frame: 5 years ]Response Rate to Avelumab + RCHOP according to the Lugano classification for Response Criteria for Non-Hodgkin Lymphoma
- Failure Free Survival [ Time Frame: 5 years ]Duration of survival without additional systemic therapy, relapse or non-relapse mortality
- Overall Survival [ Time Frame: 5 years ]Duration of patient survival
- Overall Toxicity of Treatment [ Time Frame: 12 months ]Overall toxicity as assessed by CTCAE v4.0
|Actual Study Start Date:||July 21, 2017|
|Estimated Study Completion Date:||July 2025|
|Estimated Primary Completion Date:||February 2021 (Final data collection date for primary outcome measure)|
Avelumab - Single-arm open label study
All participants will receive the following treatment:
Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments
RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.
Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles.
Other Name: MSB0010718C
The rationale and primary objective is to evaluate the feasibility of adding induction and maintenance Avelumab into the standard Rituximab, Cyclophosphamide, Doxyrubicin, Vincristine and Prednisolone (RCHOP) regimen in order to examine the effect of programmed death-ligand 1(PDL1) inhibition in patients with stage II, III and IV DLBCL.
• Immune related toxicity which requires discontinuation of Avelumab.
- Response rates (according to the Lugano classification for Response Criteria for NonHodgkin Lymphoma);
- Failure free survival;
- Overall survival;
- Overall toxicity of treatment (according to CTCAE v 4.0).
All patients (n=28) will receive Avelumab and rituximab 2 weekly for 2 cycles, then RCHOP chemotherapy 3 weekly for 6 cycles then Avelumab 2 weekly for 6 cycles.
The sequential treatment schedule has been designed for several reasons: concurrent Avelumab and RCHOP might result in reduced efficacy of Avelumab owing to the high dose prednisolone component of RCHOP; immune related toxicities of Avelumab given concurrently with RCHOP might result in chemotherapy dose delays and reduced chemotherapy efficacy; the Avelumab plus rituximab prephase will allow for the preliminary assessment of nonchemotherapy agents Avelumab plus rituximab in treatment naïve patients.
- Patients will be reviewed at baseline and prior to each cycle of treatment for toxicity
- Positron emission tomography-computed tomography (PET/CT) will be performed at baseline, after induction phase, after cycle 2 RCHOP, at end of Avelumab (Av) RCHOP and at end of maintenance phase Avelumab.
- Following completion of treatment, patients will be followed up for a total of 5 years (at 3,6,9,12,18,24,36,48 and 60 months posttreatment). No formal routine imaging will be performed during follow up. In patients with relapse, follow up only for survival will be every 3 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03244176
|Contact: Eliza Hawkes, MD||+61 3 9496 5763 ext firstname.lastname@example.org|
|Contact: Joanne Hakanson, BSc||+61 3 9496 3352 ext email@example.com|
|Heidelberg, Victoria, Australia, 3084|
|Contact: Eliza Hawkes, MD +61 3 9496 5763 ext 5763 firstname.lastname@example.org|
|Contact: Joanne Hakanson, BSc +61 3 9496 3352 ext 3352 email@example.com|
|Principal Investigator: Eliza Hawkes, MD|
|Principal Investigator: Geoff Chong, MD|
|Principal Investigator: Joseph McKendrick, MD|
|Principal Investigator:||Eliza Hawkes, MD||Austin Health|